Palliative Care COPY Flashcards
1
Q
Principles of pain management
A
- Understand cause to optimize treatment
- Appropriate level of WHO ladder
- Use adjuvants where necessary
- Use oral where possible
- Assess regularly
- Encourage patients to take an active role in the management of their pain
2
Q
Causes of pain
A
- Nociceptive
- Somatic
- Visceral
- Neuropathic
3
Q
Opioids for pain management
A
- 1st line = morphine
- Background and breakthrough
4
Q
Breakthrough pain management
A
- Regular opioid + Breakthrough opioid
- Regular opioid = typically long acting 12 or 24 hour preparations.
- Breakthrough = immediate release preparations, given PRN when pain worsens.
5
Q
Monitoring
A
- Pain charts
- Individual dose titration
6
Q
Syringe drivers
A
- SC
- Steady plasma conc. of drug
- Dose reviewed every 24 hours, titrated up/down as needed - dependent on symptoms/side effects.
- May still require breakthrough doses
7
Q
When are syringe drivers useful?
A
- Intractable pain
- Vomiting
- Severe dysphagia (patient too weak to swallow or unconscious)
- Several drugs can be combined into one syringe - management of multiple symptoms.
8
Q
Compatibility charts
A
- For syringe drivers
- Summarises compatibility information available for drug combinations
- Determines if drugs can be mixed or if they will precipitate
- Maximum concentrations
9
Q
3 examples of palliative care emergencies
A
- Malignant hypercalcaemia
- Neutropenic sepsis
- Malignant spinal cord compression (MSCC)
10
Q
Malignant hypercalcaemia
A
- Palliative care emergency
- Sign that disease has significantly progressed (most paitnets with this die within a year)
- Ca> 2.6mmol/Lt
11
Q
Malignant hypercalcaemia - treatment
A
- Fluid replacement (1-2L NaCl 0.9% over 24h)
- Given before bisphosphonates as nephrotoxic.
- Bisphosphonates: zolendronate or pamidronate
- Treatment effective for 2-4 weeks in 70-80% of pt
- Reduce dose in renal impairment
- Ca2+ levels fall after 48h and continue to decrease for 6/7 days
- Monitor
12
Q
Zolendronate
A
4mg/100ml in normal saline for 15 mins
13
Q
Pamidronate
A
- <3.5mmol/L = 60 mg
- > 3.5 mmol/L = 90 mg
- BOTH in normal saline over 2-4 hours
14
Q
Malignant hypercalcaemia - MoA
A
- Due to parathyroid hormone-related protein
- Normally expressed in cells but also secreted by tumour cells
- PTHrP stimulates bone resorption, increasing osteoclast activity (breaks down old bones, releases calcium)
- Also increases calcium reabsorption so decreases urinary excretion of calcium
- Higher serum calcium
15
Q
Malignant hypercalcaemia - Symptoms
A
- Symptoms typically present with >3mmol/L
- N+V
- Drowsiness
- Confusion
- Constipation
- Anorexia
- Fatigue
- Mood disturbances, delirium
- Symptoms are general, so regular monitoring of Ca levels is essential
16
Q
Malignant hypercalcaemia - medical emergency
A
- > 4mmol/L
- Seizures
- Arrhythmias
- Untreated will die in a few days
17
Q
Malignant spinal cord compression
A
- Palliative care emergency - urgent referral for MRI
- Complications of cancer where metastases in spine
18
Q
MSCS - Symptoms
A
- Pain
- Motor deficits
- Autonomic deficits
- Sensory deficits
19
Q
MSCC - Treatment
A
- Dexamethasone 16mg OD ASAP
- Analgesia
- Radiotherapy
- Surgery
20
Q
Spinal cord compression
A
- Pressure on the spinal cord
- Nerves in the spinal cord swell and slow down or their blood supply is blocked.
- Nerves cannot function as normal.